Benepali®

Biosimilar medicine authorized by the European Commission

Benepali®

ACTIVE PRINCIPLE:
etanercept

INDICATION:
Psoriasic arthritis
Rheumatoid Arthritis
plaque psoriasis
Ankylosing spondylitis

DATE:
14/01/2016

STATUS:
Authorized

MORE INFORMATION

BioSim Newsletter

Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.

SUBSCRIBE